Central nervous system disorders present one of the greatest challenges in life sciences today. They are the Everest of medicine – stubborn, unyielding, awkward; still unconquered many decades after other seemingly impenetrable horizons have been comprehensively mapped, even if they haven’t been entirely tamed. Like that giant looming above us, CNS disorders present a series of particular challenges that require huge amounts of highly technical know-how, teamwork, the sharing of ideas, a great deal of trial and error – and persistence.
In fact, so unique is each disorder that each is like its own vast mountain, its own world of problems to be learned and hopefully mastered – and the CNS field more like the whole Himalayan range stretching on and on. Nonetheless, they share common problems for drug developers: their biology is often complex; diagnosing them can be difficult – especially early in the course of disease; so too can be measuring their severity and how they are progressing. While oncology, immunology and rare disease medicine have been reshaped by molecular stratification, biomarkers and targeted therapies, progress in most CNS indications has been slower and less predictable.
In disorders of the brain, the target is rarely a single impaired component. More often, disease emerges from disrupted networks: genetic vulnerability, altered synaptic signalling, neuroinflammation, neuroplasticity imbalance, vascular dysfunction, environmental effects and ageing biology may all contribute to different combinations. That makes CNS drug development less like replacing a faulty part and more like trying to retune a highly adaptive system.
The Problem of Translation
As mentioned above, the first major challenge is biological complexity. Many CNS diseases are not driven by one pathway in the way that some monogenic or oncology indications can be. Even where a clear genetic driver exists, as in fragile X syndrome – the most common inherited cause of intellectual disability – the downstream effects can extend across synaptic function, RNA translation, mitochondrial biology, dendritic spine development and broader neural network pattern. Recent proteomics work in fragile X syndrome, for example, has discovered that individuals exhibit a wide range of dysregulated proteins which are thought to negatively affect synaptic plasticity and cellular function. This reinforces that CNS diseases need to be understood at the systems level rather than through a single target alone.
